-+ 0.00%
-+ 0.00%
-+ 0.00%

Gyre Therapeutics Q2 2026 net loss widens to $14.3 million; revenue falls 2% to $29.1 million

PUBT·08/07/2026 11:04:47
Listen to the news
Gyre Therapeutics Q2 2026 net loss widens to $14.3 million; revenue falls 2% to $29.1 million
  • Gyre Therapeutics posted Q2 revenue of USD 29.1 million, down 2% year over year, while GAAP basic EPS widened to a loss of USD 0.12.
  • GAAP net loss widened to USD 14.3 million from USD 2.2 million a year earlier, with operating loss deepening to USD 14.4 million.
  • R&D expense jumped to USD 19.1 million from USD 8.4 million, driven by F351 Phase 3C review costs and an NDA-acceptance milestone payment.
  • ETUARY sales rose to USD 28.0 million from USD 23.5 million, while Etorel sales fell to USD 0.3 million from USD 1.6 million.
  • China’s CDE accepted an NDA for F351 in May; Gyre affirmed full-year 2026 revenue guidance of USD 100.5 million to USD 111.0 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070700PRIMZONEFULLFEED9805930) on August 07, 2026, and is solely responsible for the information contained therein.